The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
Qing Wei(Chinese Academy of Sciences), Xiangdong Cheng(Zhejiang Cancer Hospital), Junli Xue(Shanghai East Hospital), Jianmin Fang(Yantai University), Teng Yang(Chinese Academy of Sciences), Can Hu(Zhejiang Cancer Hospital), Jiayu Zhu(Zhejiang Chinese Medical University), Peijing Li(Chinese Academy of Sciences), Lu Wang(Second Affiliated Hospital of Zhejiang University), Jiahui Chen(Zhujiang Hospital), Letao Ma(Chinese Academy of Sciences), Ziwen Zhang(Zhejiang Cancer Hospital), Lu Sun(Huazhong University of Science and Technology), Peng Guo(Zhejiang Cancer Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Xuefei Tian(Hunan University of Traditional Chinese Medicine), Takaya Shimura(Nagoya City University)
Cited by 157
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412